Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club
Automation
IT & Software
Return to: PBR Home | Automation | IT & Software

IT & Software

Advaxis receives notice of allowance for cancer immunotherapies patent in Japan Advaxis, a biotechnology company developing the next generation of cancer immunotherapies, has received a notice of allowance from the Japan Patent Office for a patent application related to the Advaxis proprietary Lm-LLO cancer immunotherapy platform technology
Automation > IT & Software > News
Lion, Moffitt Cancer Center partner to improve tumor infiltrating lymphocyte production By PBR Staff Writer
Lion Biotechnologies that develops new cancer immunotherapies based on tumor infiltrating lymphocytes (TILs) has entered into an exclusive, worldwide license agreement with Moffitt Cancer Center.
Automation > IT & Software > News biOasis releases quantitative results: siRNA-Transcendpep reduces target gene expression in the brain BIOASIS TECHNOLOGIES, a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), has announced on May 6th, 2014, that its newly discovered carrier peptide-Transcendpep-effectively delivered siRNA across the BBB and into brain cells.
Automation > IT & Software > News
See more IT & Software news

Latest IT & Software News and Insight

View all IT & Software news or find news targeted to your interests
TransCelerate selects Cognizant to develop a clinical trials collaboration platform
Cognizant has announced that it has been selected by TransCelerate BioPharma, a non-profit organization with membership representation from 19 major pharmaceutical companies, to develop a first-of-its-kind, subscription-based platform that will transform the way clinical sites collaborate with pharmaceutical companies on clinical trials.
Automation > IT & Software > News
MYOS gets notice of allowance of US Patent Application for manufacturing methods of Fortetropin
MYOS, an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, has recently received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for U.S. Patent Application Serial No. 13/765,340 covering the Company's proprietary methods of manufacturing Fortetropin, the first clinically proven natural myostatin inhibitor.
Automation > IT & Software > News
Galena Biopharma inks licensing deal with MonoSol Rx for US rights of Zuplenz
By PBR Staff Writer
US-based biopharmaceutical firm Galena Biopharma has entered into a definitive agreement to license the US rights for Zuplenz (ondansetron) oral soluble film (OSF), from MonoSol Rx, the developer of the oral soluble film technology, PharmFilm, and manufacturer of the product.
Automation > IT & Software > News
Alnylam gets notice of allowance from USPTO for new patent broadly covering conjugate-based delivery of RNA Therapeutics
Alnylam Pharmaceuticals, a leading RNAi therapeutics company, has announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for claims in the Manoharan et al. patent application 13/693,478.
Automation > IT & Software > News
Harvard Medical School, Phelan-McDermid Syndrome Foundation Contract leverages the tranSMART open-source knowledge management platform
The tranSMART Foundation has announced that the Phelan-McDermid Syndrome Foundation and the Center of Biomedical Informatics at Harvard Medical School were awarded a nearly $1 million contract from the Patient-Centered Outcomes Research Institute (PCORI) to undertake an exciting research endeavor that will leverage the tranSMART platform.
Automation > IT & Software > News
MorphoSys gets additional patents on Ylanthia in US and first patent in China
MorphoSys has announced that the US Patent and Trademark Office (USPTO) and the State Intellectual Property Office of China have granted additional patents covering the Company's latest antibody platform Ylanthia.
Automation > IT & Software > News
Agile Therapeutics announces allowance of additional patent claims for Skinfusion
Agile Therapeutics, Inc., a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, announced that the U.S. Patent and Trademark Office issued a Notice of Allowance for additional patent claims covering dosing regimens using the Company's lead product candidate Twirla (ethinyl estradiol and levonorgestrel transdermal system (AG200-15)), currently in Phase 3 development.
Automation > IT & Software > News
Integral Molecular announces patent allowance for dengue research technology
Integral Molecular, a leader in membrane protein research, announces the issuance of a new composition patent protecting dengue reporter virus particles (RVPs).
Automation > IT & Software > News
Formpipe Announces Interim Report January - June 2014
Formpipe has announced its interim report, from January to June 2014.
Automation > IT & Software > Press Releases
Formpipe Strengthens its Position in the Life Science Industry with the Acquisition of UK GXP Limited
Formpipe has acquired the UK company GXP Limited ('GXPi'), an established provider of compliance solutions for the life science industry. The acquisition strengthens Formpipe's platform for growth in the life science industry and the acquisition has positive effects such as stronger international sales and marketing organization, an expanded product offering and an attractive customer base, both in Europe and the United States.
Automation > IT & Software > Press Releases
View all IT & Software news or find news targeted to your interests

Buy the latest industry research online today!
Shire Plc : Pharmaceuticals & Healthcare - Company Profile, SWOT & Financial Report 03 October 2013 This report is a crucial resource for industry executives and anyone looking to access key information about "Shire Plc" The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. ICD Research strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report. Buy online from $250